Results 171 to 180 of about 215,011 (302)

A Chemically Defined Four‐Component Self‐Adjuvanting Tn Vaccine Activating Mincle, FcγR, and CD206 for Enhanced Antitumor Immunity

Advanced Science, EarlyView.
A fully synthetic four‐component vaccine has been developed combining Tn antigen, vizantin (Mincle agonist), rhamnose (antibody recruitment), and mannose (CD206 targeting). By synergistically activating Mincle, FcγR, and CD206 pathways, it elicits strong IgG switching and cytotoxic T‐cells, significantly inhibiting tumors in mice.
Wenbo Ming, Renyu Zhang, Xiaohui Li, Guiqi Li, Yu Niu, Deying Yang, Xiang Luo, Jun Liao, Zhongqiu Liu, Guochao Liao   +9 more
wiley   +1 more source

Material‐Encoded Synchronization of Immunogenic Cell Death With Adenosine A2A Receptor Blockade Reprograms the Tumor Microenvironment

Advanced Science, EarlyView.
A bismuth–copper diselenide–based nanoplatform (BSCS@PHY) coordinates immunogenic cell death with local A2A receptor blockade in 4T1 tumors. Thermally triggered shell melting exposes catalytic surfaces for glutathione depletion and chemodynamic ROS generation, while co‐delivering an A2AR antagonist and yeast‐wall adjuvant to enhance dendritic‐cell ...
Xiangting Yi, Hanlou Yang, Junting Huang, Pengfei Wu, Shiying Zhou, Zunde Liao, Min Han, Zishan Chen, Xiaoyu Huang, Nan Ma, Jie Zhou, Mingqiang Li, Yiling Zhong   +12 more
wiley   +1 more source

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

Advanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo, Hansen Lin, Haoqian Feng, Lei Tan, Xi Liu, Yong Huang, Junjie Cen, Jiajie Chen, Xinwei Zhou, Mingjie Lin, Wuyuan Liao, Zheyu Ai, Minyu Chen, Yinghan Wang, Wei Chen, Junhang Luo, Yanping Liang   +16 more
wiley   +1 more source

Immunosuppression therapy in the management of peripartum cardiomyopathy: A case series and literature review. [PDF]

Obstet Med, 2016
Basu J, Redman C, Ormerod O.
europepmc   +1 more source

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

Advanced Science, EarlyView.
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten, Karen Beets, Tessa Schalley, Janne Verreycken, Gayel Duran, Daphne Lintsen, Lisa Schuetz, Xue Zhong, Rinke Nieuwschepen, Melissa Schepers, Brecht Moonen, Jeroen Bogie, Jana Van Broeckhoven, Carlo Heirman, Jurgen Van den Heuvel, Bart Vanderborght, Ismael Varela, Roxanne Nouille, Lotte Jacobs, Jessica Filtjens, Sabah Kasmi, Elise Seynaeve, Veronica Mavrovouna, Jana De Vrieze, Michael A. Brehm, Sandra Maréchal, Sophie Janssens, Florence Lambolez, Niels Hellings, Stefaan De Koker, Bieke Broux   +30 more
wiley   +1 more source

Immunosuppressive Therapy [PDF]

Postgraduate Medical Journal, 1981
openaire   +2 more sources

A Pancreatitis‐Inspired Trypsinogen Nanoplatform Reprograms Tumor‐Associated Macrophages via NF‐κB for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao, Yu He, Wenhao Li, Bo Gong, Han Lin, Jianlin Shi, Yuan Yong, Wencheng Wu   +7 more
wiley   +1 more source

Letter to the Editor: Induction therapy as a long-term commitment: Lessons from comparative outcomes of alemtuzumab and basiliximab. [PDF]

World J Transplant
Galassi L, Altamura E, Azzahrani L, Facchinetti F, Ravini ML.   +4 more
europepmc   +1 more source

Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease

Advanced Science, EarlyView.
LRRK2‐mutant induced pluripotent stem cells (iPSCs) were derived from a patient with Parkinson's disease (PD). Using CRISPR/Cas9–mediated gene editing, the pathogenic LRRK2 mutations were precisely corrected, and isogenic dopaminergic neural progenitor cells (DA‐NPCs) were subsequently generated.
Qing Yan, Chongchong Xu, Jiangmei Gao, Pu Wang, Qingling Wu, Ying Jin, Binyan Lu, Mu Li, Mingting Shao, Bihai Li, Zhenghui Su, Yijng Zhang, Jianhuan Chen, Haojie An, Mengyao Huang, Xiaoji Zhuang, Yuhui Shen, Fenglin Wang, Nana Xu, Yiyan Liu, Lei Tang, Xiuling Zhong, Minyan Zhong, Jiecong Chen, Zhenhuang Wang, Xingrong Luo, Sheng Liu, RuiFeng Liu, Ling Zhang, Junhua Rao   +29 more
wiley   +1 more source

Infectious complications and transplant outcomes in durable left ventricular assist device patients receiving immunosuppressive therapy: case series. [PDF]

Eur Heart J Case Rep
Kawauchi H, Sato T, Fukushima S, Izumi C, Tsukamoto Y.   +4 more
europepmc   +1 more source